Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: The GIMEMA experience

Blood

Volumn 100, Issue 6, 2002, Pages 1972-1976

  Pulsoni, Alessandro ^{a,b,c,d,e,f,g,h,i,j,k,l}   Pagano, Livio ^{a,b,c,d,e,f,g,h,i,j,k,l}   Lo Coco, Francesco ^{a,b,c,d,e,f,g,h,i,j,k,l}   Avvisati, Giuseppe ^{a,b,c,d,e,f,g,h,i,j,k,l}   Mele, Luca ^{a,b,c,d,e,f,g,h,i,j,k,l}   Di Bona, Eros ^{a,b,c,d,e,f,g,h,i,j,k,l}   Invernizzi, Rosangela ^{a,b,c,d,e,f,g,h,i,j,k,l}   Leoni, Franco ^{a,b,c,d,e,f,g,h,i,j,k,l}   Marmont, Filippo ^{a,b,c,d,e,f,g,h,i,j,k,l}   Mele, Alfonso ^{a,b,c,d,e,f,g,h,i,j,k,l}   Melillo, Lorella ^{a,b,c,d,e,f,g,h,i,j,k,l}   Nosari, Anna Maria ^{a,b,c,d,e,f,g,h,i,j,k,l}   Pogliani, Enrico Maria ^{a,b,c,d,e,f,g,h,i,j,k,l}   Vignetti, Marco ^{a,b,c,d,e,f,g,h,i,j,k,l}   Visani, Giuseppe ^{a,b,c,d,e,f,g,h,i,j,k,l}   Zagonel, Vittorina ^{a,b,c,d,e,f,g,h,i,j,k,l}   Leone, Giuseppe ^{a,b,c,d,e,f,g,h,i,j,k,l}   Mandelli, Franco ^{a,b,c,d,e,f,g,h,i,j,k,l}  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d SAN BORTOLO HOSPITAL   (Italy)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^f Policlinico di Careggi   (Italy)

^g MOLINETTE HOSPITAL   (Italy)

^h CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

ⁱ Falck Division   (Italy)

^j SAN GERARDO HOSPITAL   (Italy)

^k UNIVERSITY OF BOLOGNA   (Italy)

^l CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; IDARUBICIN; RETINOIC ACID;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; FEMALE; GYNECOLOGIC CANCER; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SECOND CANCER; TREATMENT OUTCOME;

EID: 0037105375     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2001-12-0312     Document Type: Article

References (42)

1. Second cancers and other late side effects of cancer treatment
2. Therapy-related myeloid leukemia
3. The secondary leukemias: Challenges and research directions
4. Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors
5. Etoposide and secondary hematological malignancies: Coincidence or causality?
6. Risk of secondary leukemia after treatment with etoposide (VP-16) for Langerhans' cell hystiocytosis in Italian and Austrian-German populations
7. Therapy-related acute promyelocytic leukemia with t(15;17) (q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II: A report of two cases and a review of the literature
8. Acute promyelocytic leukemia with t(15;17) following inhibition of DNA topoisomerase II
9. The balanced and unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation
10. Potential topoisomerase II DNA-binding sites at breakpoints of a t(9;11) chromosome translocation in acute myeloid leukemia
11. Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer
12. Acute myeloid leukemia occurring as a second malignancy: GIMEMA archive of adult acute leukemia
13. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17
14. Cloning and characterization of the t(15;17) translocation breakpoint region in acute promyelocytic leukemia
15. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor a gene to a novel transcribed locus
16. Acute promyelocytic leukemia
17. Molecular remission in PML/RARa-positive acute promyelocytic leukemia by combined all-trans retinoid acid and idarubicin (AIDA) therapy
18. All-trans retinoic acid in acute promyelocytic leukemia
19. All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: Long-term follow-up of the New York study
20. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine
21. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy
22. A randomized comparison of ATRA followed by chemotherapy and ATRA plus chemotherapy, and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia
23. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARa-positive acute promyelocytic leukemia
24. Pathogenesis and management of acute promyelocytic leukemia
25. Acute promyelocytic leukemia: A curable disease
26. Therapy related acute promyelocytic leukemia: A report of 16 cases
27. Secondary acute promyelocytic leukemia: Characteristics and prognosis of 14 patients from a single institution
28. Acute promyelocytic leukemia after treatment of malignant glioma in a patient with von Recklinghausen's disease: Case report and review of the literature
29. Acute promyelocytic leukemia with t(15;17) following treatment of Hodgkin's disease-a report of 4 cases
30. Prognosis and therapy of secondary myelodysplastic syndromes
31. Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high dose cytarabine
32. Nonparametric estimation from incomplete observations
33. Acute leukemia following previous malignancies: Do acute myeloid and lymphoid leukemia have common risk factors?
34. Secondary acute leukemia: Report of GIMEMA archive of adult acute leukemia
35. Epidemiology of acute promyelocytic leukemia
36. Acute promyelocytic leukaemia: Epidemiology and risk factors: A report of the GIMEMA Italian archive of adult acute leukaemia
37. Acute lymphoblastic leukaemia occurring as second malignancy: Report of the GIMEMA archive of adult acute leukaemia
38. Multiple endocrine neoplasia type 1: Clinical and genetic topics
39. Familial cancers associated with subtypes of leukemia and non-Hodgkin's lymphoma
40. Multi drug resistance in acute promyelocytic leukemia (APL): A low PGP, LRP and MRP expression may contribute to the high sensitivity to chemotherapy of APL
41. All-trans retinoic acid (ATRA) differentiates acute promyelocytic leukemia cells independently of P-glicoprotein (P-gp) related multidrug resistance